

BioChem Solutions announced it has now committed to proceeding with the Phase III trials for Arthromir and Alphamir drugs that have been developed and derived from trioxolane. This research is being conducted under FDA protocol guidelines at the Kenya Medical Institute (KEMRI) and is piggy-backed onto the favorable results seen in the Phase II trials conducted in 2004. In these trials, two groups of 200 people will be included within the test and control groups with the testing to be completed over a three-month period and then a subsequent two-month evaluation period. Testing will be done for the treatment of acute respiratory infections, rheumatoid arthritis and HIV.<http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=462145&contenttype=newsarchive&channelID=29>